ClinicalTrials.gg
CompletedNCT04012957DREAM-NDUpdated Nov 24, 2021

Desidustat in the Treatment of Anemia in CKD

A Phase 3 interventional study of Desidustat Oral Tablet and Darbepoetin Alfa in Chronic Kidney Disease Stage 3, Anemia and Chronic Kidney Disease Stage 4, sponsored by Zydus Lifesciences Limited. Completed at 32 sites in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Zydus Lifesciences Limited · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing Darbepoetin alfa in Renal Insufficiency, Chronic — none open to participants now, 1 under way, none of them phase 3. Darbepoetin alfa · Renal Insufficiency, Chronic.

Enrollment
4th of 23
588 · median 116
Started
2019
with 1 other
Phase 3
13 of 26
none open now
Registered
24th of 26
by date

Among the 26 studies testing Darbepoetin alfa in Renal Insufficiency, Chronic, this one is the 4th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2019, is one of 13 in phase 3, and was the 24th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

None of the 26 studies testing Darbepoetin alfa in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →

About Darbepoetin alfa

Darbepoetin alfa: first FDA approval 2001 (ARANESP), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing Darbepoetin alfa in Renal Insufficiency, Chronic as a file.
02

Study summary

This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with CKD who are not on dialysis. The study will be conducted over a period of up to 30 weeks.

03

Conditions studied

  • Chronic Kidney Disease Stage 3
  • Anemia
  • Chronic Kidney Disease Stage 4
  • Chronic Kidney Disease Stage 5

Keywords

  • DREAM-ND
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Current clinical diagnosis of anemia due to CKD, baseline concentrations must be 7.0-10.0 g/dL (both inclusive) before the enrollment.
  2. Ability to understand and give for participation.
  3. Male or female patients diagnosed with CKD (stage III to V, not receiving dialysis) defined by estimated (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI) formula.
  4. Male or female, 18 to 80 years of age.
  5. Body weight > 40 kg.
  6. Subjects not on dialysis and not expected to start dialysis during the study period.
  7. Patients must not be treated with erythropoiesis-stimulating agent (ESA) therapy within 6 weeks prior to enrollment.
  8. Estimated GFR ≥10 mL/min/1.73 m2.
  9. Serum ferritin ≥100 ng/mL and/or Transferrin Saturation >20%.
  10. No iron, folate or Vitamin B12 deficiency.
  11. Females of , must agree to use one of the approved methods, from screening until completion of the follow-up visit.

Exclusion criteria

Exclusion Criteria:

  1. Prior chronic hemodialysis or chronic peritoneal dialysis treatment.
  2. Intravenous iron within 14 days prior to enrollment.
  3. Prior exposure of rhEPO analogues less than 04 weeks.
  4. Red blood cell transfusion within 8 weeks prior to enrollment.
  5. History of previous or concurrent cancer.
  6. Serologic status reflecting active or C infection or (HIV) infection.
  7. Active infection prior to enrollment.
  8. History of renal transplant.
  9. Major surgery within 90 days of the first day of study drug dosing, and minor surgery within 30 days of the first day of study drug dosing.
  10. Unable to swallow tablets or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption such as; mal-absorption syndrome, resection of the small bowel or poorly controlled inflammatory bowel disease affecting the small intestine.
  11. History of uncontrolled hemolytic anemia, idiopathic thrombocytopenic purpura (ITP) or thalassemia.
  12. Presence or a history of bleeding disorders or clinical conditions (e.g. gastrointestinal [GI] bleeding or constitutional disorders) that may increase risk of life-threatening bleeding.
  13. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  14. History of severe allergic or to products and its .
  15. Requires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists or other medications within 28 days of the first dose of study drug that in the investigator's opinion, could compromise patient safety.
  16. Pregnant and breastfeeding women.
  17. Current life-threatening illness, medical condition or organ system dysfunction which, in the Investigator's opinion, could compromise the patient's safety.
  18. Other laboratory abnormalities that, in the opinion of the investigator, would compromise the patient's safety or interfere with data interpretation.
  19. Presence of other systemic disorders or diseases (e.g., respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement) which, in the Investigator's opinion, could compromise the patient's safety.
  20. History of significant alcoholism or drug abuse within the past 1 year. History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco/nicotine products (more than 10 times per day).
  21. History of difficulty with donating blood.
  22. History or presence of any abnormalities during screening.
  23. Participants who have participated in any drug research study other than the present trial within past 3 months.
  24. Participants who have donated one unit (350 ml) of blood in the past 3 months or history of whole blood transfusion in last 120 days prior to enrollment.
  25. History of chronic inflammatory disease (RA, Celiac disease, UC, Crohns disease, Systemic Lupus Erythematosus [SLE]).
  26. In case of Diabetes mellitus patients, glycosylated () >9 %.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
588 participants (actual)

Study arms

  • Experimental
    Darbepoetin Alfa Injection

    Randomly assigned to receive Darbepoetin in a 1:1 ratio for 24 weeks.

    Drug: Darbepoetin Alfa

  • Active comparator
    Desidustat oral tablet

    Randomly assigned to receive Desidustat 100 mg in a 1:1 ratio for 24 weeks.

    Drug: Desidustat Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Hemoglobin level

    Change in Hb levels from baseline

    Time frame: 24 weeks

Secondary outcomes

  1. Hemoglobin Response

    No. of subjects with Hb response

    Time frame: 24 weeks

  2. Hemoglobin target range

    Time to achieve target range Hb level

    Time frame: 24 weeks

07

Study locations

32 sites
  • Sunrise Hospital
    Vijayawada, Andhra Pradesh 520002, India
  • Max Super Specialty Hospital
    New Delhi, Delhi 110017, India
  • Thakershey Charitable trust Hospital
    Ahmadabad, Gujarat, India
  • HCG Hospital
    Ahmedabad, Gujarat 380006, India
  • Sangini Hospital
    Ahmedabad, Gujarat 380015, India
  • GSC Medical College and Research Centre
    Ahmedabad, Gujarat 380025, India
  • BAPS Pramukh Swami Hospital
    Sūrat, Gujarat 395009, India
  • Sterling Hospital
    Vadodara, Gujarat 390007, India
  • Dhiraj General Hospital
    Vadodara, Gujarat 391760, India
  • Sapthagiri Institute of Medical Sciences
    Bangalore, Karnataka 560090, India
  • Kasturba Medical College
    Mangalore, Karnataka 575001, India
  • Amrita Institute of Medical Science
    Kochi, Kerala 682041, India
  • Government Medical College
    Kozhikode, Kerala 673008, India
  • Mahatma Gandhi Mission Medical College & Hospital
    Aurangabad, Maharashtra 431003, India
  • Nav Sanjeevani Hospital (Sankalp Speciality Healthcare Pvt. Ltd)
    Nashik, Maharashtra 422002, India
  • Noble Hospital
    Pune, Maharashtra 411013, India
  • Bhaktivedanta Hospital and Research Institute
    Thāne, Maharashtra 401107, India
  • Asian Institute Of Medical Sciences (AIMS) Hospital
    Thāne, Maharashtra 421203, India
  • Fortis Hospital
    Delhi, New Delhi 110070, India
  • Apollo Hospital
    Bhubaneswar, Orissa 751005, India
  • Sardar Patel Medical College
    Bīkaner, Rajasthan 334003, India
  • Sawai Man Singh (SMS) Medical College and Hospital
    Jaipur, Rajasthan 302004, India
  • Eternal Hospital
    Jaipur, Rajasthan 302017, India
  • Rukmani Birla Hospital
    Jaipur, Rajasthan 302018, India
  • Osmania General Hospital
    Hyderabad, Telangana 500012, India
  • Apollo Hospital
    Hyderabad, Telangana 500058, India
  • Nizams Institute of Medical Sciences
    Hyderabad, Telangana 500082, India
  • Nizams Institute of Medical Sciences
    Hyderabad, Telangana 524001, India
  • Heritage Hospitals Limited
    Varanasi, Uttar Pradesh 221311, India
  • Shri Mahant Indiresh Hospital
    Dehradun, Uttaranchal 248001, India
  • Medica Superspecialty Hospital
    Kolkata, West Bangal 700099, India
  • Peerless Hospital
    Kolkata, WEST Bengal 700094, India
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Aug 2021, 25 months.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's 25 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2019
First posted
Jul 9, 2019
StartActual
Jul 20, 2019
Primary completionActual
Aug 25, 2021
CompletionActual
Aug 25, 2021
Last update
Nov 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04012957
Responsible party
Sponsor
First posted
Jul 9, 2019
Start date
Jul 20, 2019
Primary completion
Aug 25, 2021
Completion
Aug 25, 2021
Last update
Nov 24, 2021

Study contacts

DrDeven Parmar, MD
study director · Zydus Lifesciences Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darbepoetin alfa

Start the discussion